Filing Flows › Lenz Therapeutics (LENZ) › Q3 2026 › vs Q3 2025
Lenz Therapeutics (LENZ) Q3 2026 vs Q3 2025 (year over year)
Lenz Therapeutics's revenue fell $9.1M (-73%) from $12.5M in Q3 2025 to $3.4M in Q3 2026. The biggest changes: License revenue −$11.7M (-94%); Product sales, net +$2.6M (—).
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product sales, net | $2.6M | $0 | $2.6M | — |
| License revenue | $785K | $12.5M | −$11.7M | -94% |
| Revenue | $3.4M | $12.5M | −$9.1M | -73% |
| Other income, net | $1.9M | $2.2M | −$238K | -11% |
| Net loss | $31.0M | $16.7M | $14.3M | +85% |
| Costs & expenses | $36.3M | $31.4M | $4.9M | +16% |
| Operating costs | $36.3M | $31.4M | $4.9M | +16% |
| SG&A | $35.8M | $27.6M | $8.3M | +30% |
| Operating cash sources | $31.0M | $16.7M | $14.3M | +85% |
| Depreciation & amortization | $109K | $125K | −$16K | -13% |
| Share-based compensation | $4.1M | $3.5M | $665K | +19% |
| Working capital & other | $4.4M | $4.5M | −$103K | -2% |
| Cash used in operations | $22.3M | $8.6M | $13.7M | +160% |
| Net loss absorbed | $31.0M | $16.7M | $14.3M | +85% |
Questions
How much did Lenz Therapeutics's revenue grow year over year in Q3 2026?
Lenz Therapeutics's revenue fell $9.1M (-73%) from $12.5M in Q3 2025 to $3.4M in Q3 2026.
What drove Lenz Therapeutics's revenue change in Q3 2026?
License revenue −$11.7M (-94%); Product sales, net +$2.6M (—).